Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research

NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the addition of Joyce Sutcliffe, Ph.D., as vice president of research.

Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research

ANN ARBOR, MI | Posted on October 30th, 2007

Sutcliffe brings 26 years of experience in the discovery and design of new antibiotics, with particular emphasis on understanding and overcoming antibiotic resistance. She joined the NanoBio team from Rib-X Pharmaceuticals, where she served as vice president of biology and chief research scientist.

During her tenure at Rib-X Pharmaceuticals and previously at Pfizer and Abbott, Sutcliffe focused on leveraging knowledge about target-based resistance to help design novel antibiotics that are potent against organisms with antibiotic resistance. She also led teams that evaluated efficacy and pharmacokinetics in animal disease models to ensure safety and compatibility with other drugs.

"Antibiotic resistance drives the need for new treatments against tenacious infectious microorganisms that continue to mutate," said Sutcliffe. "For example the rampant explosion of MRSA (methicillin-resistant Staphylococcus aureus) in the community has led to a need for safe anti- infectives. These bacteria are no longer resistant to just antibiotics but have become multidrug-resistant by adding other resistance mechanisms to their armamentarium.

"NanoBio's deep pipeline of topical anti-infectives and mucosal vaccines is particularly compelling, given the platform technology poses a very low risk of resistance while having broad antimicrobial activity against a wide range of infections," Sutcliffe said.

NanoBio's line of anti-infectives are designed to wage a two-pronged attack against bacteria, viruses, and fungi using safe detergents along with high-energy nanoemulsions to physically disrupt pathogen membranes and lyse microbes, said James Baker, Jr., M.D., founder and CSO of NanoBio Corporation. The absence of a specific metabolic target significantly reduces the likelihood of triggering resistant infections, he added.

"The addition of Dr. Sutcliffe, an internationally recognized anti- infective expert, will enable NanoBio to accelerate the number of product candidates we take into the clinic for preventing and treating a wide range of infections," said Baker.


About NanoBio(R) Corporation
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

For more information, please click here

NanoBio® Corporation

2311 Green Road, Suite A
Ann Arbor, Michigan 48105

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 20th, 2018

Extracellular vesicles could be personalized drug delivery vehicles March 15th, 2018

Scientists Use Nanotechnology to Detect Molecular Biomarker for Osteoarthritis March 13th, 2018

Polymer nanoparticle shows ability to locate and treat breast tumors March 13th, 2018


Design approach developed for important new catalysts for energy conversion and storage: New method could aid in design of pharmaceuticals and optical and data storage materials March 21st, 2018

RIT researchers improve fabrication process of nano-structures for electronic devices: Use of indium gallium phosphide with I-MacEtch processing shows promise for more cost effective fabrication and increased performance in devices from photonics to telecommunications March 20th, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 20th, 2018

Leti and Inac Show Path to Creating Building Blocks of Quantum Processors With 28Si isotope in a CMOS Line: Fabrication of Isotopically Enriched, Industry-Compatible Wafers Points Way To Realizing Silicon Spin Quantum Bits with Enhanced Fidelity March 20th, 2018

Appointments/Promotions/New hires/Resignations/Deaths

Jim Barnhart Joins Nanometrics as Senior Vice President of Operations March 15th, 2018

Jonathan Chou to Join Nanometrics as Chief Financial Officer February 26th, 2018

Ocean Optics Grows Sales Organization with Executive Appointments: Henry Langston promoted, Christine Stannard joins spectral sensing product developer December 23rd, 2017

Emmanuel Sabonnadiere is Leti’s New CEO November 28th, 2017

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project